Close Menu

NEW YORK – Thermo Fisher Scientific on Wednesday reported a 6 percent year-over-year increase in its third quarter revenues, driven by growth across most of its business segments.

Total Q3 revenues for the Waltham, Massachusetts-based company were $6.27 billion, up from $5.92 billion in the year-ago quarter and beating the average Wall Street estimate of $6.18 billion. Organic revenue grew 7 percent and foreign currency effects decreased revenue by 1 percent.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

In PLOS this week: transcriptomic and genomic analysis of prostate cancer by ancestry, genes linked to liver function in Korean cohort, and more.

British Columbia is incorporating genomics into its tracking of the ongoing COVID-19 outbreak, Business in Vancouver reports.

An analysis by the Personalized Medicine Coalition finds that about a quarter of new drugs approved in 2019 by the US Food and Drug Administration were personalized medicines.

The governor of New York has proposed a five-year plan to study the genomes of people with or who are at high risk of developing Alzheimer's disease.